Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms.

Autor: Lee WH; Divisions of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.; Department of Internal Medicine, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu, Taiwan.; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan., Lin CC; Divisions of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.; Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan., Tsai CH; Divisions of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.; Department of Medical Education and Research, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan., Tien FM; Divisions of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan., Lo MY; Divisions of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.; Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan., Tseng MH; Tai-Chen Cell Therapy Center, National Taiwan University, Taipei, Taiwan., Kuo YY; Tai-Chen Cell Therapy Center, National Taiwan University, Taipei, Taiwan., Yu SC; Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan., Liu MC; Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan., Yuan CT; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.; Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan.; Department of Pathology, National Taiwan University Hospital Cancer Center Branch, Taipei, Taiwan., Yang YT; Divisions of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.; Department of Internal Medicine, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu, Taiwan.; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan., Chuang MK; Divisions of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.; Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan., Ko BS; Divisions of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. bskomd@ntu.edu.tw.; Tai-Chen Cell Therapy Center, National Taiwan University, Taipei, Taiwan. bskomd@ntu.edu.tw.; Department of Hematological Oncology, National Taiwan University Cancer Center, Taipei, Taiwan. bskomd@ntu.edu.tw., Tang JL; Divisions of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.; Department of Hematological Oncology, National Taiwan University Cancer Center, Taipei, Taiwan., Sun HI; Tai-Chen Cell Therapy Center, National Taiwan University, Taipei, Taiwan., Chuang YK; Tai-Chen Cell Therapy Center, National Taiwan University, Taipei, Taiwan., Tien HF; Divisions of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.; Department of Internal Medicine, Far-Eastern Memorial Hospital, New Taipei, Taiwan., Hou HA; Divisions of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. hsinanhou@ntu.edu.tw.; General Medicine, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. hsinanhou@ntu.edu.tw., Chou WC; Divisions of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.; Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Jazyk: angličtina
Zdroj: Blood cancer journal [Blood Cancer J] 2024 Apr 09; Vol. 14 (1), pp. 57. Date of Electronic Publication: 2024 Apr 09.
DOI: 10.1038/s41408-024-01031-9
Abstrakt: In 2022, two novel classification systems for myelodysplastic syndromes/neoplasms (MDS) have been proposed: the International Consensus Classification (ICC) and the 2022 World Health Organization (WHO-2022) classification. These two contemporary systems exhibit numerous shared features but also diverge significantly in terminology and the definition of new entities. Thus, we retrospectively validated the ICC and WHO-2022 classification and found that both systems promoted efficient segregation of this heterogeneous disease. After examining the distinction between the two systems, we showed that a peripheral blood blast percentage ≥ 5% indicates adverse survival. Identifying MDS/acute myeloid leukemia with MDS-related gene mutations or cytogenetic abnormalities helps differentiate survival outcomes. In MDS, not otherwise specified patients, those diagnosed with hypoplastic MDS and single lineage dysplasia displayed a trend of superior survival compared to other low-risk MDS patients. Furthermore, the impact of bone marrow fibrosis on survival was less pronounced within the ICC framework. Allogeneic transplantation appears to improve outcomes for patients diagnosed with MDS with excess blasts in the ICC. Therefore, we proposed an integrated system that may lead to the accurate diagnosis and advancement of future research for MDS. Prospective studies are warranted to validate this refined classification.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: